At a glance
- Originator Bristol-Myers Squibb
- Class Antiallergics; Antiasthmatics; Antipsoriatics; Small molecules
- Mechanism of Action 5-lipoxygenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Asthma; Hypersensitivity; Psoriasis
Most Recent Events
- 15 Jun 1995 New profile
- 15 Jun 1995 Discontinued-Preclinical for Allergy in Japan (Unknown route)
- 15 Jun 1995 Discontinued-Preclinical for Asthma in Japan (Unknown route)